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RepoRt
There are a large number of patients with sickle cell disease 
(SCD) in the Baltimore metropolitan area. In 2009, the Centers 
for Disease Control and Prevention revealed that SCD affects 
1 of every 500 African Americans, and that more than 70,000 
people in the United States are reported to have the disease.1 
The Maryland Department of Health and Mental Hygiene 
reports that African Americans make up almost 30 percent 
of the population of Maryland, which represents the fourth 
largest percentage (after Mississippi, Louisiana, and Georgia) 
of African Americans in the United States.2 Additionally, in 
Baltimore, African Americans represent 63.7 percent of the 
population according to the 2010 Census.3 Approximately 
80 infants with SCD are born in Maryland each year, and of 
these, 47.5 percent live in the Baltimore area. Between July 1, 
1985, and June 20, 2006, a total of 1680 babies with a sickling 
disorder requiring follow-up were identified through newborn 
screening. If all of these patients survived to age 65, there 
would be approximately 3520 patients with SCD older than 
21 years of age living in Maryland.2 However, SCD remains 
associated with significant morbidity and mortality, and 
consequently, only 1700 adults with SCD were estimated to 
live in Maryland in 2006.2 The Hospital Discharge Database 
of the Maryland Health Care Commission revealed that from 
2000 to 2005, there were 13,724 hospital admissions for adults 
with SCD, with an average length of stay of 4.94 days, and a 
total cost of $97 million.2
The Johns Hopkins Hospital has separate adult and 
pediatric hematology services. The Sickle Cell Center for 
Adults is a center dedicated to providing both health and social 
services for adult persons with SCD who predominantly live in 
the Baltimore and Washington, D.C., areas. The center is now 
in its third year of operation and provides regularly scheduled 
outpatient visits, screening for hydroxyurea eligibility, genetic 
counseling, 7-days-a-week outpatient pain management, 
education, wound care, and social services. Since opening, the 
center has treated 611 total and 485 active adult patients with 
SCD. The center is an honorary chapter of the national Sickle 
Cell Disease Association of America.
The center has a full-time hematologist devoted to the 
care of persons with SCD. There are also several other adult 
hematologists within the division with expertise in SCD who 
serve as a backup for the center’s medical director. The center 
also has full-time physician assistants who address both 
acute and chronic medical issues and act as a liaison to other 
medical specialists throughout the hospital. Additionally, 
the center has developed a relationship with the emergency 
room to decrease waiting times for patients with SCD 
and has established continuity of care through follow-up 
appointments in the clinic (see http://www.hopkinsmedicine.
org/hematology/sicklecell/).
The pediatrics department has nine full-time and part-
time faculty members, four of whom have a primary research 
interest in SCD. The pediatric hematology division at The 
Johns Hopkins Hospital is a National Heart, Lung, and Blood 
Institute–funded Basic and Translational Sickle Cell Research 
Center. All children with SCD have a primary hematologist 
for long-term care as an outpatient, but their daily inpatient 
care is managed by a designated attending hematologist on 
service. There is also a weekly 2-hour SCD multidisciplinary 
care conference for inpatient and outpatient management 
issues.
Lastly, since 2007, the Sidney Kimmel Comprehensive 
Cancer Center at The Johns Hopkins Hospital has been 
actively investigating the use of bone marrow transplant as 
a treatment modality for patients with clinically significant 
SCD. Specifically, the center has been conducting a phase 
2 trial investigating the combination of chemotherapy, 
total-body irradiation, and nonmyeloablative allogeneic 
hematopoietic stem cell transplantation on mortality and 
progression-free survival for patients with SCD. They have 
been recruiting both children and adults (2–70 years of age) 
who have a history of significant SCD–related morbidity, 
such as a previous stroke, acute chest syndrome, multiple 
red blood cell (RBC) alloantibodies, or osteonecrosis. Patient 
recruitment for this study is expected to continue through 
November 2012.
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Transfusion Protocol and Donor Selection
The Transfusion Medicine Division and Hemapheresis 
and Transfusion Support (HATS) at The Johns Hopkins 
Hospital provide comprehensive RBC transfusion and 
apheresis support for the SCD population. In addition to 
providing routine RBC transfusions and RBC exchanges, they 
provide emergency RBC exchanges for severely ill pediatric 
and adult SCD patients at any time.
The current transfusion protocol at The Johns Hopkins 
Hospital for patients with SCD involves providing hemoglobin 
S (HbS)–negative, leukocyte-reduced, and ABO- and 
D-matched RBCs. Historically, when a new patient with SCD 
was first seen at Johns Hopkins, a serologically derived RBC 
phenotype was performed. However, in addition to serologic 
phenotyping, the transfusion service currently performs a 
DNA-based RBC antigen phenotype, making the procurement 
of a pretransfusion blood sample less critical in certain clinical 
situations. All phenotype information, both serologically 
derived and genotype derived, is archived and accessible via 
the transfusion medicine computer system. All blood intended 
for the SCD population is tested before release for sickling 
hemoglobin via a kit (Dade® Sickle-Sol®, Siemens Healthcare 
Diagnostics, Inc., Newark, DE). The service neither specifically 
nor routinely provides ethnically matched, fresh (donor units 
collected within 14 days), irradiated, or cytomegalovirus-
seronegative blood. There is no limitation to the age of the 
donor units. Moreover, phenotypically matched blood is not 
routinely provided if the patient does not demonstrate, or 
have a history of, an alloantibody or autoantibody. However, 
if an SCD transfusion patient does form an alloantibody or 
autoantibody, the known RBC phenotype is then used to assist 
in antibody identification. The transfusion service specifically 
avoids all antigens to which the patient has the corresponding 
alloantibody, and then prophylactically matches for all RBC 
antigens that are routinely associated with clinically significant 
alloantibodies, including those antigens in the following blood 
group systems: Rh, Kell, Kidd, Duffy, and MNS.
Within the last year, The Johns Hopkins Hospital 
transfusion service has initiated a new program to supplement 
the blood components provided by our routine blood supplier 
for the SCD patient population. This grant-funded initiative 
was modeled after several other successful programs 
throughout the country. The program involves recruiting 
healthy, HbS–negative, African American donors from the 
Baltimore community to donate apheresis RBCs to inpatient 
and outpatient individuals with SCD who require transfusion 
support. The goal of this program is to develop and maintain 
a registry of genotype-predicted phenotypes for both our SCD 
patient population and designated donors, and to actively 
match specific donors to transfusion-dependent SCD patients 
with a similar phenotype or genotype. This program is still 
in its infancy, and the transfusion service intends to evaluate 
its efficacy in the future. This program has been developed in 
association with ongoing efforts by the transfusion service 
and the clinical hematology services to serve as advocates for 
minority donation programs run by the American Red Cross.
Emergency Protocols
The Johns Hopkins Hospital transfusion service 
occasionally encounters some difficulty obtaining phenotypi-
cally matched blood for patients with SCD in a timely manner, 
especially when the need for blood is urgent, the patient has a 
rare or complex RBC phenotype, or large quantities are needed 
for an RBC exchange. The management of a patient with SCD 
in need of blood relies heavily on the clinical consultation 
between the attending hematologist and the attending blood 
bank physician. If the need for transfusion is deemed clinically 
urgent, and the patient is determined to need antigen-
matched blood, every attempt is made to provide timely, fully 
phenotype-matched blood through the local blood provider. 
However, if this plan is determined not to be temporally 
feasible, blood is obtained that at least respects the patient’s 
known alloantibody(ies), and prophylactically matches as 
many additional antigens as the situation allows.
Warm autoantibodies also complicate the selection of 
appropriate blood for patients with SCD. As most if not all 
RBC units will be crossmatch incompatible in such situations, 
the transfusion service again makes every attempt to obtain 
phenotypically matched blood for the patient, even if the 
patient has no current or historic alloantibodies.4 Least 
incompatible blood is not routinely used at our institution,5 
as phenotypically matched blood is thought to be as safe 
as the patient’s own blood. As time allows, the transfusion 
service will also perform adsorption studies to exclude new or 
previously unidentified underlying alloantibodies. However, 
this step may not be feasible before transfusion because of the 
urgent need for blood in these patients.
Protocol Outcomes
Formation of alloantibodies and autoantibodies to RBC 
antigens is a known significant complication for patients with 
SCD. The incidence of alloimmunization in patients with 
SCD ranges from 2 to 50 percent depending on the study.6–8 
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Alloantibody formation is undesirable, as it creates the 
potential for serologic incompatibility, delays and complicates 
treatment plans, and increases the risk of delayed hemolytic 
transfusion reactions. By routinely determining the RBC 
antigen genotype or phenotype for all patients with SCD, we 
are optimally prepared to acutely manage the unexpected 
formation of either an autoantibody or an alloantibody.
The rationale for this methodology is threefold. First, as 
a scientific community, we still do not have criteria capable 
of distinguishing those patients who are likely to form an 
alloantibody (an immune responder) from those who will not 
(an immune nonresponder). Although, on average, 25 percent 
of patients with SCD will form an alloantibody, studies indicate 
that up to 75 percent of patients will not, regardless of how 
many transfusions they receive.9,10 Moreover, previous studies 
have demonstrated that those who form an RBC alloantibody 
are at greater risk for forming additional RBC antibodies.11,12 
Consequently, our transfusion service identifies those who 
are likely to be immune responders as those who have 
demonstrated the ability to form their first RBC alloantibody.4 
Second, antigen matching is financially costly. Although each 
blood provider is different, hundreds of additional dollars can 
be spent per RBC unit to obtain phenotype-matched blood. 
This issue is of particular concern at our institution owing to 
the very large number of patients with SCD supported by our 
hospital. Lastly, particular RBC antigens or antigen phenotype 
combinations are rare, and consequently these phenotypes 
require prudent conservation. For example, Fya and Jkb are 
associated with clinically significant alloantibodies. Although 
not rare individually, RBCs lacking both antigens are only 
found in about 9 percent of the general donor population.13 
Not surprisingly, the number of RBC units lacking these two 
antigens is limited. Specifically requesting Fy(a–) and Jk(b–) 
RBC units for only those patients who have demonstrated 
alloantibodies or are immune responders, logistically, places 
less strain on the blood provider and the blood supply than 
requesting  Fy(a–) and Jk(b–) blood for all patients lacking 
those antigens. In summary, unlike transfusion policies that 
require antigen-matched RBC units for all patients with 
SCD, our current transfusion protocol limits requests for 
phenotype-matched RBC units to only those patients who are 
likely immune responders, defends against the added cost of 
antigen matching, and limits the use of rare or uncommon 
RBC phenotypes.
Two small studies from our own institution have 
supported the concept that extended phenotype matching 
can be a successful approach for preventing alloimmunization 
and delayed hemolytic transfusion reactions. First, King et al. 
previously reported that none of eight chronically transfused 
pediatric patients with both SCD and at least one alloantibody 
developed a subsequent alloantibody or evidence of a delayed 
hemolytic transfusion reaction when transfused with multiple 
(median, 111.6 units per patient) prophylactic antigen-matched 
RBCs.10 Although not in patients with SCD, Shirey et al. 
similarly demonstrated that none of 12 patients who presented 
with warm autoimmune hemolytic anemia developed an 
underlying alloantibody despite being transfused with 
multiple prophylactic antigen-matched RBCs (mean, 15 units 
per patient).14 Moreover, despite 149 total transfusions, none 
of the 12 patients in this cohort developed adverse reactions 
to transfusion, and all of the study patients had the expected 
increases in hemoglobin and hematocrit values.14
Studies from other institutions support the efficacy of an 
extended antigen-matched RBC protocol. The incidence of 
alloimmunization in patients receiving this protocol is noted to 
be 0 to 7 percent, depending on the study.11,15,16 This incidence 
rate is notably less than the previously noted incidence of 
alloimmunization (25%) without antigen matching.11,12 The 
largest study to date using an extended antigen-matched 
RBC protocol revealed that in 99 patients evaluated during 
a 6.6 (median)-year period, only 4 (4%) developed a new 
alloantibody (anti-Lea, -Kpa, and two with anti-M) when 
individuals with partial D phenotypes were not included.11
Some institutions have used partial antigen-matching 
protocols such as matching for Rh and K to prevent the most 
common alloantibodies. These protocols have had reasonable 
success; however, previous studies have shown that 
alloimmunization to the unmatched antigens can occur.17–19
Although several studies demonstrate the efficacy of an 
extended antigen-matched RBC protocol, limiting the use of 
such a protocol until the formation of a first alloantibody is less 
well established. Unfortunately, retrospectively determining 
the effectiveness of our unique SCD transfusion protocol is 
difficult. Specifically, patients with SCD in the Baltimore 
metropolitan area often receive RBC transfusions acutely at 
local hospitals outside of the Hopkins system, many of which 
have transfusion policies very different from our own (i.e., no 
phenotype matching). As a result, alloantibody formation in 
the context of a patient who has been on a phenotype-matched 
RBC protocol at our institution cannot be definitively used as 
evidence of a protocol failure.
Since the transfusion service started routinely genotyping 
patients with SCD in the last few years, however, a cohort of 
138 fully genotyped patients with SCD has been identified. 
This cohort is under active rigorous investigation, and future 
publications from our institution should be able to elucidate 
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the effectiveness of our protocol in this population, both in 
general and in terms of our newly initiated African American 
community donor program.
Summary
The Baltimore area has a large number of patients with 
SCD because of the large number of African Americans in our 
immediate urban community. The American Red Cross in our 
region, by fully understanding the needs of The Johns Hopkins 
Hospital and our unique patient population, has established a 
mechanism to readily provide fully, or close-to-fully, antigen-
matched blood when requested. Consequently, our service 
determines the RBC genotype-derived phenotype of all patients 
with SCD before their first transfusion, and provides extended 
antigen-matched blood only when the patient demonstrates 
his or her first autoantibody or alloantibody. Although one 
small study at our institution and larger studies from other 
institutions suggest that extended phenotype matching may be 
effective at preventing delayed hemolytic transfusion reactions 
and alloimmunization in patients with SCD, the success of 
our unique program is an area of active investigation, and 
will be clarified in the coming years. In conclusion, although 
many SCD experts believe that prophylactic antigen matching 
should be the standard of care, the transfusion physicians at 
our institution remain unconvinced that phenotype matching 
RBCs for all patients with SCD, before they have shown 
the ability to make alloantibodies, is either cost-effective or 
medically prudent.
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